Table 2.
Differences between the physician’s final diagnosis and the reviewer diagnosis as shown by JAK2V617F test status
| JAK2V617F test status | |||||
|---|---|---|---|---|---|
| Not tested (n=55)a | Negative (n=61) |
Positive (n=88) |
Total (n=204) |
||
| PV diagnosis | Physician (%) | 41 (75 %) | 8 (13 %) | 72 (82 %) | 121 (59 %) |
| Reviewer (%) | 24 (44 %) | 2 (3 %) | 64 (73 %) | 90 (44 %) | |
| p value | <0.001 | 0.04 | 0.011 | ||
| Other MPN diagnosisb | Physician (%) | 4 (7 %) | 2 (2 %) | 16 (18 %) | 22 (11 %) |
| Reviewer (%) | 8 (15 %) | 2 (3 %) | 24 (27 %) | 34 (17 %) | |
| All MPN diagnoses | Physician (%) | 45 (82 %) | 10 (16 %) | 88 (100 %) | 143 (70 %) |
| Reviewer (%) | 32 (58 %) | 4 (7 %) | 88 (100 %) | 124 (61 %) | |
| p value | <0.001 | 0.04 | 1 | ||
| Non-MPN diagnosisc | Physician (%) | 10 (18 %) | 52 (85 %) | 0 (0 %) | 61 (30 %) |
| Reviewer (%) | 23 (42 %) | 57 (93 %) | 0 (0 %) | 80 (39 %) | |
a
Sample size is determined by physician diagnosis
b
MPNs include ET, PMF, and other cases where the exact MPN diagnosis was uncertain
c
Includes secondary polycythemia, stress erythrocytosis, and normal